Skip to main content

BeOne Medicines Ltd. (ONC) Stock Analysis

Range Bound setup · Temp Headwind edge

Buy WaitModerate Confidence

Healthcare · Biotechnology

Wait for pullback to $300.13. Weak momentum — blocks BUY_NOW at $303.38. Engine's entry $300.13 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum.

BeOne Medicines is a global oncology company with approximately $5.3 billion in 2025 revenues, led by BRUKINSA (BTK inhibitor, approved in 77 markets, $3.9 billion in 2025 sales) and TEVIMBRA (PD-1 antibody, approved in 51 markets). It achieved GAAP net income for the first time... Read more

$303.38+23.5% A.UpsideScore 6.4/10#9 of 157 Biotechnology
QualityF-score9 / 9FCF yield2.98%
Entry $300.13(Ma50 Sticky)Stop $280.82Target $370.24(analyst − 10%)A.R:R 3.4:1Setup A.R:R 3.7:1
Analyst target$411.38+35.6%27 analysts
$370.24our TP
$303.38price
$411.38mean
$501

Wait for pullback to $300.13. Weak momentum — blocks BUY_NOW at $303.38. Engine's entry $300.13 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.00, quality 7.5/10, growth 10.0/10). Score 6.4/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.

Val5.9Qual7.5Grw10.0Mom2.5Sent8.0Ins5.0Peer4.3Tech5.0Risk6.16.4OVERALL

Recent Developments — BeOne Medicines Ltd.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.5 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Risks
Concentration risk — Product: BRUKINSA
Negative momentum

Key Metrics

P/E (TTM)67.0
P/E (Fwd)31.0
Mkt Cap$30.8B
EV/EBITDA515.7
Profit Mgn8.9%
ROE12.4%
Rev Growth35.5%
Beta0.50
DividendNone
Rating analysts15

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C1.61bearish
IV46%normal
Max Pain$250-17.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductBRUKINSA
    10-K Item 1: 'BRUKINSA generated $3.9 billion in sales in 2025, is approved in over 75 markets'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Rsi
4.5
Ma Position
7.2
Volume distribution (falling OBV)Below 200-MA but MA still rising (+1.6%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 2.5<4.5A.R:R 3.4 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
57 · Neutral
↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $289.54Resistance $322.45

Price Targets

$281
$300
$370
A.Upside+22.0%
A.R:R3.4:1
Setup A.R:R (at entry)3.7:1

Position Sizing

ConvictionHigh conviction
Suggested %1.2%
Max %2.4%
RegimeRisk-Off

Risk Alerts

! Momentum score 2.5/10 — below 4.5 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-05 (77d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ONC stock a buy right now?

Wait for pullback to $300.13. Weak momentum — blocks BUY_NOW at $303.38. Engine's entry $300.13 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.00, quality 7.5/10, growth 10.0/10). Target $370.24 (+22.0%), stop $280.82 (−8.0%), Setup A.R:R 3.7:1. Score 6.4/10, moderate confidence.

What is the ONC stock price target?

Take-profit target: $370.24 (+23.5% upside). Target $370.24 (+22.0%), stop $280.82 (−8.0%), Setup A.R:R 3.7:1. Stop-loss: $280.82.

What are the risks of investing in ONC?

Concentration risk — Product: BRUKINSA; Negative momentum.

Is ONC overvalued or undervalued?

BeOne Medicines Ltd. trades at a P/E of 67.0 (forward 31.0). TrendMatrix value score: 5.9/10. Verdict: Buy (Wait for Entry).

What do analysts say about ONC?

15 analysts cover ONC with a consensus score of 4.1/5. Average price target: $411.

What does BeOne Medicines Ltd. do?BeOne Medicines is a global oncology company with approximately $5.3 billion in 2025 revenues, led by BRUKINSA (BTK...

BeOne Medicines is a global oncology company with approximately $5.3 billion in 2025 revenues, led by BRUKINSA (BTK inhibitor, approved in 77 markets, $3.9 billion in 2025 sales) and TEVIMBRA (PD-1 antibody, approved in 51 markets). It achieved GAAP net income for the first time in 2025 and operates with nearly 12,000 employees worldwide.

Related stocks: INCY (Incyte Corporation) · ARGX (argenx SE) · HALO (Halozyme Therapeutics, Inc.) · ALNY (Alnylam Pharmaceuticals, Inc.) · TLX (Telix Pharmaceuticals Limited)